Amgen Struggles To Spark Enbrel Growth, Faces Increased Competition
Executive Summary
Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters